Form 4: LivaNova Director Susan Podlogar's RSU Vesting

LivaNova PLC Director Susan M. Podlogar acquired 2,355 ordinary shares through RSU vesting, with 269 shares withheld for tax obligations.

Summary

• Susan M. Podlogar, a Director of LivaNova PLC, had 2,355 restricted stock units (RSUs) vest on December 15, 2025.
• These vested RSUs were settled in 2,355 ordinary shares of LivaNova PLC.
• Concurrently, 269 ordinary shares were disposed of at a price of $63.06 per share to satisfy tax liabilities related to the vesting.
• Following these transactions, Podlogar directly beneficially owns 2,086 ordinary shares.
• The RSUs were granted on December 15, 2024, with a one-year vesting schedule under the LivaNova PLC 2015 Incentive Award Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. It's a routine compensation event (expected), but it does show a director increasing their direct ownership, which is generally viewed favorably as it aligns interests. The tax withholding is a standard part of the process and not negative in itself.

Positives

• A director's equity stake in the company increased through the vesting of 2,355 restricted stock units, aligning management interests with shareholders.
• The vesting demonstrates the company's commitment to its incentive award plan for directors.

Negatives

• 269 ordinary shares were withheld to cover tax liabilities, representing a reduction in the total shares received from the RSU vesting.

Future Outlook

The filing does not contain specific forward-looking statements or guidance beyond the completion of the RSU vesting event.

Industry Context

This transaction is a routine insider compensation event, common across all industries, where executive and director compensation often includes equity awards like RSUs to align their interests with long-term shareholder value. It does not provide specific insights into broader industry trends for medical technology companies like LivaNova.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of director compensation is a standard practice across publicly traded companies, including those in the medical technology sector, aligning director incentives with company performance.
• The one-year vesting schedule for the RSUs is a common duration for such awards, particularly for non-employee directors, ensuring continued engagement and oversight.
• The withholding of shares to cover tax liabilities upon vesting is a standard and efficient mechanism for managing tax obligations associated with equity compensation, widely adopted by companies like Medtronic, Abbott Laboratories, and Boston Scientific.

Stakeholder Impact

• Shareholders: The transaction increases a director's direct ownership, potentially signaling confidence and better alignment of interests between management and shareholders.
• Employees: The RSU plan is part of the company's incentive structure, which can positively influence employee morale and retention if similar plans are available to other key personnel.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction involving the vesting of Restricted Stock Units and subsequent tax withholding. It does not provide new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The increase in a director's beneficial ownership is a minor positive, but insufficient to alter a 'hold' stance based solely on this filing.

Keywords

LivaNova PLC, LIVN, Form 4, SEC filing, Restricted Stock Units, RSU vesting, insider transaction, director ownership, equity compensation, share acquisition, tax withholding